Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
5.7M
Short interest
settlement 2026-10-15
5.7
Days to cover
-2.6 days vs prior
68.3%
Short share of volume
2026-11-02
2
Fails to deliver
settlement 2026-09-29
Tue 3 Nov
Next earnings
estimated date
-$5.2M
Insider flow, 90 days
0 buys, 14 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TARS is 5,731,409 shares, down 396,475 shares over the last month. Over the last 48 readings it ranged from 4,551,689 shares (31 December 2025) to 8,856,844 shares (30 June 2025). At the reported average volume of 1.0M shares a day that is 5.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tars" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,731,409 | -5.6% | 1,004,501 | 5.71 |
| 2026-09-30 | 6,070,928 | -0.9% | 732,012 | 8.29 |
| 2026-09-15 | 6,127,884 | +1.9% | 923,426 | 6.64 |
| 2026-08-31 | 6,011,550 | +0.2% | 613,155 | 9.80 |
| 2026-08-14 | 5,997,475 | -0.3% | 801,093 | 7.49 |
| 2026-07-31 | 6,016,830 | +4.0% | 914,420 | 6.58 |
| 2026-07-15 | 5,783,063 | -1.8% | 1,819,244 | 3.18 |
| 2026-06-30 | 5,889,643 | +18.3% | 943,186 | 6.24 |
| 2026-06-15 | 4,979,585 | -2.9% | 559,334 | 8.90 |
| 2026-05-29 | 5,125,873 | +4.5% | 690,081 | 7.43 |
| 2026-05-15 | 4,905,282 | +1.8% | 855,835 | 5.73 |
| 2026-04-30 | 4,817,273 | +5.7% | 642,331 | 7.50 |
| 2026-04-15 | 4,558,352 | -0.4% | 344,367 | 13.24 |
| 2026-03-31 | 4,575,347 | -8.9% | 508,711 | 8.99 |
| 2026-03-13 | 5,021,787 | -5.7% | 495,079 | 10.14 |
| 2026-02-27 | 5,326,451 | -2.5% | 781,995 | 6.81 |
| 2026-02-13 | 5,460,762 | -6.1% | 555,556 | 9.83 |
| 2026-01-30 | 5,813,209 | +8.3% | 543,889 | 10.69 |
| 2026-01-15 | 5,365,607 | +17.9% | 524,194 | 10.24 |
| 2025-12-31 | 4,551,689 | -33.1% | 814,954 | 5.59 |
| 2025-12-15 | 6,807,544 | -4.3% | 453,939 | 15.00 |
| 2025-11-28 | 7,116,863 | -0.7% | 416,462 | 17.09 |
| 2025-11-14 | 7,166,734 | -1.5% | 490,687 | 14.61 |
| 2025-10-31 | 7,279,055 | +3.6% | 488,801 | 14.89 |
| 2025-10-15 | 7,025,255 | -3.0% | 692,812 | 10.14 |
| 2025-09-30 | 7,243,632 | -5.1% | 636,808 | 11.37 |
| 2025-09-15 | 7,634,147 | +10.2% | 832,786 | 9.17 |
| 2025-08-29 | 6,925,599 | -5.7% | 533,007 | 12.99 |
| 2025-08-15 | 7,339,962 | -9.8% | 803,354 | 9.14 |
| 2025-07-31 | 8,136,900 | -0.9% | 561,118 | 14.50 |
| 2025-07-15 | 8,208,464 | -7.3% | 563,522 | 14.57 |
| 2025-06-30 | 8,856,844 | +9.2% | 644,925 | 13.73 |
| 2025-06-13 | 8,111,634 | +0.5% | 551,901 | 14.70 |
| 2025-05-30 | 8,073,126 | +3.8% | 484,050 | 16.68 |
| 2025-05-15 | 7,779,546 | -6.4% | 873,354 | 8.91 |
| 2025-04-30 | 8,308,925 | -0.8% | 655,639 | 12.67 |
| 2025-04-15 | 8,378,489 | +9.5% | 693,077 | 12.09 |
| 2025-03-31 | 7,651,107 | +3.4% | 729,772 | 10.48 |
| 2025-03-14 | 7,403,040 | +0.8% | 593,663 | 12.47 |
| 2025-02-28 | 7,342,164 | +3.7% | 791,300 | 9.28 |
| 2025-02-14 | 7,082,922 | -3.5% | 454,438 | 15.59 |
| 2025-01-31 | 7,339,031 | +4.5% | 460,777 | 15.93 |
| 2025-01-15 | 7,020,304 | -4.2% | 994,905 | 7.06 |
| 2024-12-31 | 7,328,028 | -2.9% | 520,937 | 14.07 |
| 2024-12-13 | 7,543,047 | +5.0% | 506,601 | 14.89 |
| 2024-11-29 | 7,180,505 | +0.6% | 492,680 | 14.57 |
| 2024-11-15 | 7,140,778 | -12.5% | 1,069,725 | 6.68 |
| 2024-10-31 | 8,157,528 | -15.7% | 931,859 | 8.75 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of TARS volume is 68.3%, down 14.9 points over the last five sessions. Over the last 30 readings it ranged from 29.9% (28 September 2026) to 83.3% (21 October 2026). The latest reading is 7.1 points above the 30-session average of 61.2%, on 138K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 94K | 138K | 68.3% | 1,128 |
| 2026-10-30 | 120K | 156K | 76.6% | 0 |
| 2026-10-29 | 105K | 135K | 77.9% | 0 |
| 2026-10-28 | 122K | 168K | 72.2% | 0 |
| 2026-10-27 | 86K | 123K | 69.8% | 0 |
| 2026-10-26 | 139K | 167K | 83.2% | 2,985 |
| 2026-10-23 | 111K | 203K | 54.6% | 27,321 |
| 2026-10-22 | 150K | 195K | 77.0% | 207 |
| 2026-10-21 | 374K | 448K | 83.3% | 400 |
| 2026-10-20 | 212K | 319K | 66.5% | 6,518 |
| 2026-10-19 | 105K | 207K | 51.0% | 1,867 |
| 2026-10-16 | 182K | 292K | 62.3% | 1,888 |
| 2026-10-15 | 247K | 412K | 59.9% | 21,992 |
| 2026-10-14 | 142K | 282K | 50.5% | 0 |
| 2026-10-13 | 131K | 354K | 36.9% | 10 |
| 2026-10-12 | 138K | 289K | 47.8% | 0 |
| 2026-10-09 | 80K | 154K | 51.6% | 2 |
| 2026-10-08 | 99K | 216K | 45.9% | 0 |
| 2026-10-07 | 58K | 121K | 48.1% | 0 |
| 2026-10-06 | 109K | 155K | 70.7% | 0 |
| 2026-10-05 | 102K | 189K | 54.0% | 0 |
| 2026-10-02 | 145K | 294K | 49.2% | 0 |
| 2026-10-01 | 293K | 415K | 70.6% | 20 |
| 2026-09-30 | 252K | 335K | 75.2% | 0 |
| 2026-09-29 | 73K | 118K | 61.7% | 0 |
| 2026-09-28 | 68K | 227K | 29.9% | 0 |
| 2026-09-25 | 181K | 284K | 63.8% | 80 |
| 2026-09-24 | 105K | 236K | 44.6% | 0 |
| 2026-09-23 | 145K | 225K | 64.3% | 0 |
| 2026-09-22 | 176K | 254K | 69.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 29 September 2026, the fails-to-deliver balance in TARS is 2 shares, down 247 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (29 September 2026) to 132,239 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-29 | 2 | $76.81 | $154 |
| 2026-09-08 | 249 | $90.78 | $23K |
| 2026-09-02 | 1,875 | $74.05 | $139K |
| 2026-08-07 | 10 | $65.33 | $653 |
| 2026-08-05 | 30,000 | $61.11 | $1.8M |
| 2026-07-23 | 7,966 | $57.58 | $459K |
| 2026-07-20 | 28 | $59.85 | $2K |
| 2026-07-17 | 314 | $57.69 | $18K |
| 2026-07-14 | 5,316 | $59.31 | $315K |
| 2026-07-01 | 122,000 | $62.94 | $7.7M |
| 2026-06-30 | 43,653 | $61.26 | $2.7M |
| 2026-06-29 | 132,239 | $62.92 | $8.3M |
| 2026-06-24 | 37,119 | $66.17 | $2.5M |
| 2026-06-08 | 9,788 | $59.28 | $580K |
| 2026-06-04 | 661 | $58.76 | $39K |
| 2026-06-03 | 3,725 | $57.41 | $214K |
| 2026-06-01 | 9,574 | $59.40 | $569K |
| 2026-05-29 | 50 | $59.54 | $3K |
| 2026-05-26 | 246 | $62.26 | $15K |
| 2026-05-19 | 2,000 | $62.82 | $126K |
| 2026-05-18 | 19 | $62.48 | $1K |
| 2026-05-07 | 22,576 | $64.76 | $1.5M |
| 2026-04-30 | 35 | $60.67 | $2K |
| 2026-04-24 | 8 | $60.97 | $488 |
| 2026-04-17 | 7 | $67.72 | $474 |
| 2026-04-14 | 24,747 | $72.65 | $1.8M |
| 2026-04-13 | 283 | $72.56 | $21K |
| 2026-04-07 | 7 | $70.19 | $491 |
| 2026-04-06 | 4 | $70.12 | $280 |
| 2026-04-01 | 273 | $70.15 | $19K |
Insider trades
SEC Form 4, newest first. JSONInsiders at TARS reported 14 open-market sells worth $5.2M in the last 90 days and no open-market buys. Latest filing: LINK WILLIAM J PHD (Director) on 2026-09-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | LINK WILLIAM J PHD | Director | Sell | 66 | $80.01 | $5K | 94K |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Sell | 759 | $79.00 | $60K | 95K |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Sell | 12K | $78.33 | $915K | 95K |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Exercise or conversion | 201 | price not stated in the filing | not stated | 107K |
| 2026-09-15 | YARNO WENDY L | Director | Exercise or conversion | 302 | price not stated in the filing | not stated | 17K |
| 2026-09-15 | PYOTT DAVID E I | Director | Exercise or conversion | 201 | price not stated in the filing | not stated | 10K |
| 2026-09-04 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 2K | $90.00 | $143K | 2K |
| 2026-09-04 | Neervannan Seshadri | Chief Operating Officer | Sell | 5K | $85.00 | $388K | 79K |
| 2026-09-04 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 2K | $85.00 | $135K | 3K |
| 2026-09-04 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5K | $90.00 | $485K | 3K |
| 2026-09-04 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5K | $85.00 | $458K | 8K |
| 2026-09-04 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 3K | $91.27 | $265K | 828K |
| 2026-09-04 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 7K | $90.27 | $641K | 831K |
| 2026-09-02 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 2K | $80.00 | $127K | 5K |
| 2026-09-02 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5K | $80.00 | $431K | 13K |
| 2026-09-02 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 10K | $80.06 | $801K | 838K |
| 2026-09-01 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5K | $73.86 | $340K | 19K |
| 2026-06-17 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 5K | $61.81 | $335K | 848K |
| 2026-06-17 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 5K | $61.24 | $281K | 853K |
| 2026-06-16 | Farrow Jeffrey S | See Remarks | Sell | 14K | $60.95 | $877K | 57K |
| 2026-06-15 | LINK WILLIAM J PHD | Director | Sell | 2K | $62.94 | $121K | 107K |
| 2026-06-15 | LINK WILLIAM J PHD | Director | Sell | 11K | $61.97 | $655K | 109K |
| 2026-06-15 | Goodrich Katherine | Director | Sell | 3K | $62.08 | $183K | 2K |
| 2026-06-15 | Farrow Jeffrey S | See Remarks | Exercise or conversion | 28K | price not stated in the filing | not stated | 71K |
| 2026-06-12 | Goldberg Andrew D. | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 20K |
| 2026-06-12 | YARNO WENDY L | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 17K |
| 2026-06-12 | Goodrich Katherine | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 5K |
| 2026-06-12 | CHAUDHURI BHASKAR | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 12K |
| 2026-06-12 | LINK WILLIAM J PHD | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 119K |
| 2026-06-12 | Morrison Scott W | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 8K |
| 2026-04-24 | PYOTT DAVID E I | Director | Exercise or conversion | 1K | price not stated in the filing | not stated | 1K |
| 2026-03-20 | Neervannan Seshadri | Chief Operating Officer | Sell | 3K | $66.75 | $200K | 83K |
| 2026-03-19 | Wahl Bryan | General Counsel | Sell | 4K | $67.00 | $283K | 64K |
| 2026-03-19 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 4K | $67.00 | $280K | 35K |
| 2026-03-19 | Neervannan Seshadri | Chief Operating Officer | Sell | 5K | $67.00 | $307K | 86K |
| 2026-03-19 | Mottiwala Aziz | Chief Commercial Officer | Sell | 4K | $67.00 | $297K | 61K |
| 2026-03-19 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 390 | $67.00 | $26K | 23K |
| 2026-03-19 | Farrow Jeffrey S | See Remarks | Sell | 2K | $67.00 | $146K | 43K |
| 2026-03-19 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 12K | $67.00 | $802K | 33K |
| 2026-03-18 | Wahl Bryan | General Counsel | Sell | 4K | $68.71 | $283K | 68K |
| 2026-03-18 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 4K | $68.71 | $280K | 39K |
| 2026-03-18 | Neervannan Seshadri | Chief Operating Officer | Sell | 4K | $68.71 | $248K | 90K |
| 2026-03-18 | Mottiwala Aziz | Chief Commercial Officer | Sell | 4K | $68.71 | $298K | 66K |
| 2026-03-18 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 379 | $68.71 | $26K | 24K |
| 2026-03-18 | Farrow Jeffrey S | See Remarks | Sell | 2K | $68.71 | $147K | 46K |
| 2026-03-18 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 12K | $68.71 | $802K | 45K |
| 2026-03-17 | Wahl Bryan | General Counsel | Sell | 4K | $69.42 | $284K | 72K |
| 2026-03-17 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 4K | $69.42 | $280K | 43K |
| 2026-03-17 | Neervannan Seshadri | Chief Operating Officer | Sell | 3K | $69.42 | $217K | 94K |
| 2026-03-17 | Mottiwala Aziz | Chief Commercial Officer | Sell | 4K | $69.42 | $298K | 70K |
| 2026-03-17 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 375 | $69.42 | $26K | 24K |
| 2026-03-17 | Farrow Jeffrey S | See Remarks | Sell | 2K | $69.42 | $147K | 48K |
| 2026-03-17 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 11K | $69.42 | $762K | 57K |
| 2026-03-16 | LINK WILLIAM J PHD | Director | Sell | 493 | $69.75 | $34K | 116K |
| 2026-03-16 | LINK WILLIAM J PHD | Director | Sell | 8K | $69.03 | $578K | 117K |
| 2026-03-16 | LINK WILLIAM J PHD | Director | Sell | 4K | $68.09 | $247K | 125K |
| 2026-03-15 | Lin Elizabeth Yeu | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 24K |
| 2026-03-15 | Azamian Bobak R. | President/CEO and Board Chair | Exercise or conversion | 66K | price not stated in the filing | not stated | 68K |
| 2026-03-15 | Farrow Jeffrey S | See Remarks | Exercise or conversion | 13K | price not stated in the filing | not stated | 50K |
| 2026-03-15 | Mottiwala Aziz | Chief Commercial Officer | Exercise or conversion | 26K | price not stated in the filing | not stated | 75K |
| 2026-03-15 | Neervannan Seshadri | Chief Operating Officer | Exercise or conversion | 26K | price not stated in the filing | not stated | 97K |
| 2026-03-15 | Wahl Bryan | General Counsel | Exercise or conversion | 24K | price not stated in the filing | not stated | 76K |
| 2026-03-15 | Whitfield Dianne C. | Chief Human Resources Officer | Exercise or conversion | 24K | price not stated in the filing | not stated | 47K |
| 2026-03-04 | Neervannan Seshadri | Chief Operating Officer | Sell | 8K | $76.67 | $641K | 71K |
| 2026-01-02 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 893 | $82.93 | $74K | 23K |
| 2026-01-02 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 835 | $81.90 | $68K | 24K |
| 2026-01-02 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 8K | $80.71 | $656K | 25K |
| 2026-01-02 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 6K | $80.09 | $458K | 33K |
| 2025-12-24 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 557 | $83.54 | $47K | 858K |
| 2025-12-24 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 5K | $82.41 | $449K | 859K |
| 2025-12-16 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 2K | $79.50 | $165K | 22K |
| 2025-12-16 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 7K | $80.10 | $592K | 39K |
| 2025-12-16 | Neervannan Seshadri | Chief Operating Officer | Gift | 475 | $0.00 | $0 | 475 |
| 2025-12-16 | Neervannan Seshadri | Chief Operating Officer | Gift | 950 | $0.00 | $0 | 79K |
| 2025-12-15 | Goodrich Katherine | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2025-12-15 | Lin Elizabeth Yeu | Chief Medical Officer | Exercise or conversion | 7K | price not stated in the filing | not stated | 24K |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Sell | 5K | $81.50 | $388K | 0 |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Sell | 6K | $80.71 | $458K | 5K |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Sell | 1K | $82.39 | $95K | 129K |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Sell | 6K | $81.75 | $516K | 130K |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Sell | 5K | $80.80 | $408K | 136K |
| 2025-12-04 | Azamian Bobak R. | President/CEO and Board Chair | Gift | 52K | $0.00 | $0 | 2K |
| 2025-09-24 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6K | $55.37 | $332K | 812K |
| 2025-09-16 | LINK WILLIAM J PHD | Director | Gift | 2K | $0.00 | $0 | 141K |
| 2025-09-15 | Morrison Scott W | Director | Exercise or conversion | 1K | price not stated in the filing | not stated | 5K |
| 2025-09-08 | LINK WILLIAM J PHD | Director | Sell | 27K | $57.00 | $1.5M | 143K |
| 2025-08-11 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6K | $50.00 | $300K | 818K |
| 2025-06-17 | Farrow Jeffrey S | See Remarks | Sell | 14K | $40.42 | $550K | 37K |
| 2025-06-16 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 1K | $41.08 | $41K | 8K |
| 2025-06-16 | Farrow Jeffrey S | See Remarks | Exercise or conversion | 28K | price not stated in the filing | not stated | 50K |
| 2025-06-13 | LINK WILLIAM J PHD | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 170K |
| 2025-06-13 | Morrison Scott W | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
| 2025-06-13 | YARNO WENDY L | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 14K |
| 2025-06-13 | Goldberg Andrew D. | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 17K |
| 2025-06-13 | CHAUDHURI BHASKAR | Director | Exercise or conversion | 3K | price not stated in the filing | not stated | 9K |
| 2025-06-13 | Lin Elizabeth Yeu | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 9K |
| 2025-06-09 | Mottiwala Aziz | Chief Commercial Officer | Sell | 18K | $43.76 | $766K | 48K |
| 2025-03-24 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6K | $50.00 | $300K | 824K |
| 2025-03-20 | Farrow Jeffrey S | See Remarks | Sell | 1K | $50.11 | $59K | 22K |
| 2025-03-20 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 9K | $50.11 | $428K | 54K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON43 Form 144 notices on file for TARS worth $32.3M at the prices reported; 10 in the last 90 days worth $18.6M. Latest: Neervannan Seshadri filed on 2026-09-04 to sell 4,564 shares ($388K) from 2026-09-04.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-04 | Neervannan SeshadriOfficer | 5K | $388K | 0.010% | 2026-09-04 | Fidelity Brokerage Services LLC |
| 2026-09-04 | Lin Elizabeth YeuMember of immediate family of any of the foregoing | 3K | $278K | 0.007% | 2026-09-04 | Fidelity Brokerage Services LLC |
| 2026-09-04 | Lin Elizabeth YeuOfficer | 11K | $943K | 0.025% | 2026-09-04 | Fidelity Brokerage Services LLC |
| 2026-09-02 | Mottiwala AzizFormer Officer | 8K | $654K | 0.018% | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-09-02 | Lin Elizabeth YeuMember of immediate family of any of the foregoing | 2K | $127K | 0.004% | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-09-02 | Lin Elizabeth YeuOfficer | 5K | $431K | 0.012% | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-09-01 | Mottiwala AzizFormer Officer | 78K | $5.7M | 0.177% | 2026-09-01 | Fidelity Brokerage Services LLC |
| 2026-09-01 | Lin Elizabeth YeuOfficer | 5K | $340K | 0.010% | 2026-09-01 | Fidelity Brokerage Services LLC |
| 2026-08-25 | Mottiwala AzizFormer Officer | 81K | $5.8M | 0.185% | 2026-08-25 | Fidelity Brokerage Services LLC |
| 2026-08-19 | Mottiwala AzizFormer Officer | 53K | $3.8M | 0.121% | 2026-08-19 | Fidelity Brokerage Services LLC |
| 2026-06-16 | Farrow Jeffrey SOfficer | 14K | $877K | 0.033% | 2026-06-16 | Fidelity Brokerage Services LLC |
| 2026-06-15 | Goodrich KatherineDirector | 3K | $183K | 0.007% | 2026-06-15 | Fidelity Brokerage Services LLC |
| 2026-03-20 | Neervannan SeshadriOfficer | 3K | $200K | 0.007% | 2026-03-20 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Whitfield Dianne C.Officer | 4K | $280K | 0.010% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Wahl BryanOfficer | 4K | $283K | 0.010% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Neervannan SeshadriOfficer | 5K | $307K | 0.011% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Mottiwala AzizOfficer | 4K | $297K | 0.010% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Lin Elizabeth YeuOfficer | 390 | $26K | 0.001% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Farrow Jeffrey SOfficer | 2K | $146K | 0.005% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-19 | Azamian Bobak R.Officer, Director | 12K | $802K | 0.028% | 2026-03-19 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Whitfield Dianne C.Officer | 4K | $280K | 0.010% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Wahl BryanOfficer | 4K | $283K | 0.010% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Neervannan SeshadriOfficer | 4K | $248K | 0.008% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Mottiwala AzizOfficer | 4K | $298K | 0.010% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Lin Elizabeth YeuOfficer | 379 | $26K | 0.001% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Farrow Jeffrey SOfficer | 2K | $147K | 0.005% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Azamian Bobak R.Officer, Director | 12K | $802K | 0.027% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Wahl BryanOfficer | 4K | $283K | 0.010% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Whitfield Dianne C.Officer | 4K | $280K | 0.009% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Neervannan SeshadriOfficer | 3K | $217K | 0.007% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Mottiwala AzizOfficer | 4K | $298K | 0.010% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Lin Elizabeth YeuOfficer | 375 | $26K | 0.001% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Farrow Jeffrey SOfficer | 2K | $147K | 0.005% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-17 | Azamian Bobak R.Officer, Director | 11K | $762K | 0.026% | 2026-03-17 | Fidelity Brokerage Services LLC |
| 2026-03-16 | WILLIAM J LINKDIRECTOR | 13K | $860K | 0.029% | 2026-03-16 | MERRILL LYNCH |
| 2026-03-04 | Neervannan SeshadriOfficer | 8K | $641K | 0.020% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-01-02 | Whitfield Dianne C.Officer | 16K | $1.3M | 0.037% | 2026-01-02 | Fidelity Brokerage Services LLC |
| 2025-12-29 | BOBAK AZAMIANOFFICER | 6K | $495K | 0.014% | 2025-12-24 | MERRILL LYNCH |
| 2025-12-16 | Whitfield Dianne C.Officer | 7K | $592K | 0.017% | 2025-12-16 | Fidelity Brokerage Services LLC |
| 2025-12-16 | Lin Elizabeth YeuOfficer | 2K | $165K | 0.005% | 2025-12-16 | Fidelity Brokerage Services LLC |
| 2025-12-15 | William LinkDirector | 10K | $846K | 0.025% | 2025-12-15 | Merrill Lynch |
| 2025-12-15 | WILLIAM J LINKDIRECTOR | 13K | $1.0M | 0.029% | 2025-12-15 | MERRILL LYNCH |
| 2025-09-24 | Bobak Azamian Living TrustOfficer | 6K | $332K | 0.014% | 2025-09-24 | MERRILL LYNCH |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of TARS in their latest filing, all on Schedule 13G (passive). The largest reported stake is Deep Track Capital, LP at 8.5% of the class (3,600,000 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 1 | JANUS HENDERSON GROUP Ltd.parent holding company | 2.8M | 6.5% | 2026-06-30 |
| 2026-05-15 | 13G | JANUS HENDERSON GROUP PLCparent holding company | 2.2M | 5.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Deep Track Capital, LPinvestment adviser, other entity | 3.6M | 8.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Deep Track Biotechnology Master Fund, Ltd.corporation | 3.6M | 8.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | David Kroinparent holding company, individual | 3.6M | 8.5% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 20 | PRUDENTIAL FINANCIAL INCparent holding company | 1.8M | 4.3% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | Jennison Associates LLCinvestment adviser | 1.7M | 4.0% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL MANAGEMENT, LLCother entity | 1.2M | 2.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | KEVIN TANGindividual | 1.2M | 2.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 785K | 1.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS, LPpartnership | 346K | 0.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS III, INCcorporation | 44K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS IV, INCcorporation | 15K | 0.0% | 2025-12-31 |
13F holders
Tracked managers holding TARS at their latest 13F. JSON6 of the 30 tracked managers held TARS at their latest 13F, $155.3M in total at quarter-end prices. Millennium Management is the largest at $89.8M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.4M | $89.8M | 0.03% | +863K |
| D. E. Shaw & Co. | 2026-06-30 | 711K | $44.7M | 0.02% | -81K |
| Citadel Advisors | 2026-06-30 | 242K | $15.2M | 0.00% | +78K |
| AQR Capital Management | 2026-06-30 | 42K | $2.6M | 0.00% | +12K |
| Two Sigma Investments | 2026-06-30 | 36K | $2.3M | 0.00% | +17K |
| Renaissance Technologies | 2026-06-30 | 9K | $585K | 0.00% | -64K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Tarsus Pharmaceuticals reported revenue of $173.9M, up 69.4% from the same quarter a year earlier, and net loss of $18.6M (-0.43 diluted EPS). In FY 2025 it generated -$12.5M of operating cash flow. As of 2026-06-30, cash was $204.6M against $72.8M of debt.
- Cash
- $204.6M
- Debt
- $72.8M
- Equity
- $346.7M
- Total assets
- $611.1M
- Shares outstanding
- 43,882,996
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $173.9M | -$18.6M | -10.7% | -0.43 |
| Q1 FY 2026 | 2026-03-31 | $162.1M | -$7.0M | -4.3% | -0.16 |
| Q4 FY 2025derived | 2025-12-31 | $151.7M | -$8.4M | -5.5% | n/a |
| Q3 FY 2025 | 2025-09-30 | $118.7M | -$12.6M | -10.6% | -0.30 |
| Q2 FY 2025 | 2025-06-30 | $102.7M | -$20.3M | -19.8% | -0.48 |
| Q1 FY 2025 | 2025-03-31 | $78.3M | -$25.1M | -32.1% | -0.64 |
| Q4 FY 2024derived | 2024-12-31 | $66.4M | -$23.1M | -34.8% | n/a |
| Q3 FY 2024 | 2024-09-30 | $48.1M | -$23.4M | -48.7% | -0.61 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $451.4M | -$66.4M | -$12.5M | $9.9M | n/a | n/a |
| FY 2024 | 2024-12-31 | $183.0M | -$115.6M | -$83.0M | $1.6M | n/a | n/a |
| FY 2023 | 2023-12-31 | $17.4M | -$135.9M | -$117.5M | $1.5M | n/a | n/a |
| FY 2022 | 2022-12-31 | $25.8M | -$62.1M | -$49.0M | $506K | n/a | n/a |
| FY 2021 | 2021-12-31 | $57.0M | -$13.8M | $3.7M | $586K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
Tarsus Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Tarsus Pharmaceuticals (TARS), SEC CIK 1819790, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-29.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-04.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1819790Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of TARS is sold short?
5,731,409 shares were held short at the 2026-10-15 settlement, 5.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TARS's daily short volume?
On 2026-11-02, 94,425 of the 138,205 TARS shares reported to FINRA were sold short, 68.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TARS have fails to deliver?
The SEC's latest file shows 2 TARS shares failed to deliver at settlement 2026-09-29. Fails are reported per settlement date and published twice a month with a lag.
Are TARS insiders buying or selling?
Insiders at TARS reported 14 open-market sells worth $5.2M in the last 90 days and no open-market buys. Latest filing: LINK WILLIAM J PHD (Director) on 2026-09-15.
Have TARS insiders filed to sell?
43 Form 144 notices on file for TARS worth $32.3M at the prices reported; 10 in the last 90 days worth $18.6M. Latest: Neervannan Seshadri filed on 2026-09-04 to sell 4,564 shares ($388K) from 2026-09-04.
Who owns 5% or more of TARS?
5 holders report 5% or more of TARS in their latest filing, all on Schedule 13G (passive). The largest reported stake is Deep Track Capital, LP at 8.5% of the class (3,600,000 shares), filed 2026-05-15 for an event on 2026-03-31.
What did TARS report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Tarsus Pharmaceuticals reported revenue of $173.9M, up 69.4% from the same quarter a year earlier, and net loss of $18.6M (-0.43 diluted EPS). In FY 2025 it generated -$12.5M of operating cash flow. As of 2026-06-30, cash was $204.6M against $72.8M of debt.
Which tracked 13F managers own TARS?
6 of the 30 tracked 13F managers held TARS shares at their latest filing, $155.3M in all. The largest: Izzy Englander's Millennium Management (1.4M shares, $89.8M), D. E. Shaw & Co. (711K shares, $44.7M), Ken Griffin's Citadel Advisors (242K shares, $15.2M), Cliff Asness's AQR Capital Management (42K shares, $2.6M), Two Sigma Investments (36K shares, $2.3M), Renaissance Technologies (9K shares, $585K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.